Quick Takeaways
- Sujay Kango has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value is not available.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Sujay Kango
- Location
- Bridgewater, NJ
- Signature
- /s/ Adam M. Veness, as attorney-in-fact for Sujay Kango
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Sujay Kango and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: ACCELERON PHARMA INC ().
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Sujay Kango
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| XLRN | ACCELERON PHARMA INC | EVP, Chief Commercial Officer | 19 Nov 2021 | |||
| DNTH | Dianthus Therapeutics, Inc. /DE/ | Director | 04 Mar 2025 | |||
| INFI | INFINITY PHARMACEUTICALS, INC. | Director | 30 Mar 2022 | |||
| LITS | MEI Pharma, Inc. | Director | 29 Sep 2023 |
Insider Transactions Reported by Sujay Kango:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.